USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about brivaracetam. Some of the dosage forms listed on this page may not apply to the brand name Briviact.
Common side effects of Briviact include: acute psychosis, balance impairment, dizziness, drowsiness, fatigue, sedated state, abnormal behavior, abnormal gait, aggressive behavior, agitation, anxiety, apathy, asthenia, ataxia, depressed mood, depression, hallucination, hypersomnia, lacrimation, lethargy, nervousness, nystagmus disorder, paranoid ideation, psychomotor agitation, vertigo, irritability, emotional lability, malaise, and restlessness. See below for a comprehensive list of adverse effects.
Applies to brivaracetam: oral solution, oral tablet
Other dosage forms:
Along with its needed effects, brivaracetam (the active ingredient contained in Briviact) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking brivaracetam:
Incidence not known
Some side effects of brivaracetam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to brivaracetam: intravenous solution, oral liquid, oral tablet
The more commonly reported adverse events have included somnolence/sedation, dizziness, fatigue, and nausea/vomiting.
Very common (10% or more): Somnolence/sedation (up to 27%), dizziness and disturbances in gait and coordination (up to 16%); fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy)
Common (1% to 10%): Cerebellar coordination and balance disturbances, convulsion, vertigo
This drug causes dose-dependent increases in somnolence and fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy). In clinical trials, somnolence and fatigue-related adverse reactions were reported in 25%, 20%, 26%, and 27% of patients receiving at least 50 mg/day, 50 mg/day, 100 mg/day, and 200 mg/day, respectively. Adverse reactions related to dizziness, gait and coordination disturbances including vertigo, ataxia, nystagmus occurred in 16% of patients.
Common (1% to 10%): Depression, anxiety, insomnia, irritability
Uncommon (0.1% to 1%): Suicidal ideation, psychotic disorder, aggression, agitation
Psychiatric adverse events have been commonly reported. During clinical trials, approximately 13% of patients (compared to 8% on placebo) reported psychiatric events which included irritability, anxiety, nervousness, aggression, belligerence, anger, agitation, restlessness, depression, depressed mood, tearfulness, apathy, altered mood, mood swings, affect lability, psychomotor hyperactivity, abnormal behavior, adjustment disorder, psychotic disorder, hallucinations, paranoia, acute psychosis and psychotic behavior. A total of 1.7% of adult patients discontinued treatment because of psychiatric reactions (compared to 1.3% of placebo). In pediatric trials, psychiatric events were generally similar.
Common (1% to 10%): Infusion site pain
Frequency not reported: Hypersensitivity, bronchospasm, angioedema
Common (1% to 10%): Decreased appetite, decreased weight
Common (1% to 10%): Decreased WBC
Uncommon (0.1% to 1%): Neutropenia
In clinical trials, at least 1.8% of patients had at least 1 clinically significant decreased WBC (compared to 1.1% of placebo).
Common (1% to 10%): Nausea, vomiting, constipation
Common (1% to 10%): Upper respiratory tract infections, cough
Common (1% to 10%): Influenza
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020